Inozyme Pharma to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Inozyme Pharma, Inc. (Nasdaq: INZY), a biopharmaceutical company focused on treating rare diseases, announced CEO Axel Bolte's participation in two upcoming investor conferences. The first is the Jefferies London Healthcare Conference on November 17, from 9:10-9:40am GMT. The second is the Piper Sandler 34th Annual Healthcare Conference on November 29, from 12:30-12:55pm ET. Inozyme is developing INZ-701, a potential first-in-class enzyme therapy, currently in Phase 1/2 trials for ENPP1 and ABCC6 Deficiencies, addressing serious diseases linked to pathologic mineralization.

BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief executive officer, will participate in the following investor conferences:

• The Jefferies London Healthcare Conference. The presentation will take place on Thursday, November 17 from 9:10-9:40am GMT / 4:10-4:40am ET.
• The Piper Sandler 34th Annual Healthcare Conference. The fireside chat will take place on Tuesday, November 29 from 12:30-12:55pm ET.

Replays can be accessed from the Investor Relations section of Inozyme’s website under events and will be available for a limited time following the events.

About Inozyme Pharma

Inozyme Pharma, Inc. (Nasdaq: INZY) is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. We are developing INZ-701, a potential first-in-class enzyme therapy, to address pathologic mineralization and intimal proliferation which can drive morbidity and mortality in these severe diseases. INZ-701 is currently in Phase 1/2 clinical trials for the treatment of ENPP1 Deficiency and ABCC6 Deficiency.

For more information, please visit www.inozyme.com and follow us on LinkedIn, Twitter, and Facebook.

Contacts
Investors:
Inozyme Pharma
Stefan Riley, Director of Investor Relations and Corporate Communications
(857) 330-8871
stefan.riley@inozyme.com        

Media:
SmithSolve
Matt Pera
(973) 886-9150
matt.pera@smithsolve.com

FAQ

What conferences will Inozyme Pharma participate in November 2022?

Inozyme Pharma will participate in the Jefferies London Healthcare Conference on November 17 and the Piper Sandler 34th Annual Healthcare Conference on November 29, 2022.

What is the focus of Inozyme Pharma's research?

Inozyme Pharma focuses on developing therapeutics for rare diseases related to pathologic mineralization and intimal proliferation.

What is INZ-701 and its current status?

INZ-701 is a potential first-in-class enzyme therapy currently in Phase 1/2 clinical trials for ENPP1 and ABCC6 Deficiencies.

When is Axel Bolte's presentation at the Jefferies London Healthcare Conference?

Axel Bolte's presentation at the Jefferies London Healthcare Conference is scheduled for November 17, 2022, from 9:10-9:40am GMT.

How can I access replays of Inozyme Pharma's conference presentations?

Replays of Inozyme Pharma's conference presentations will be available in the Investor Relations section of their website for a limited time after the events.